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A B S T R A C T
Background
Aspirin is widely prescribed for patients with a diagnosis of vascular dementia. In a survey of UK geriatricians and psychiatrists 80%
of patients with clinical diagnoses of vascular dementia were prescribed aspirin. However, a number of queries remain unanswered. Is
there convincing evidence that aspirin benefits patients with vascular dementia? Does aspirin affect cognition and behaviour, or improve
prognosis? Does the risk of cerebral or gastric haemorrhage outweigh any benefit?
Objectives
To assess the randomised trial evidence for efficacy and safety of aspirin in the treatment of vascular dementia.
Search methods
We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 12 March 2012 using the
terms: aspirin OR “acetylsalicylic acid”. ALOIS contains records of clinical trials identified frommonthly searches of a number of major
healthcare databases, numerous trial registries and grey literature sources.
In addition, relevant websites were searched and some journals were handsearched. Specialists in the field were approached for unpub-
lished material and any publications found were searched for additional references.
Selection criteria
Randomised controlled trials investigating the effect of aspirin for vascular dementia were eligible for inclusion.
Data collection and analysis
Retrieved studies were analysed independently by both review authors. Methodology and results were critically appraised and outcomes
scanned included cognition, behavioural change, mortality and institutionalisation.
Main results
No trials were eligible for inclusion in this review.
1Aspirin for vascular dementia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
The most recent search for references to relevant research was carried out in March 2012. No trials were found for inclusion in this
systematic review.
Low-dose aspirin is frequently used as ’treatment as normal’ in control groups and as a baseline treatment in pharmacological trials.
There is still no good evidence that aspirin is effective in treating patients with a diagnosis of vascular dementia.
There is increasing concern that low-dose aspirin is associated with increased risk of haemorrhages.
Further research is needed to assess the effect of aspirin on cognition, and on other outcomes such as haemorrhages, mortality,
institutionalisation and behaviour.
However, the feasibility of such research is limited by a number of factors, including the widespread use of low-dose aspirin for secondary
prevention of cerebrovascular and cardiovascular conditions, and its low cost and lack of patent, which limit commercial interest in
investing in these studies. In addition, there is increasing evidence of its potential to cause harm from haemorrhages, especially gastric
and cerebral haemorrhages that can be fatal.
P L A I N L A N G U A G E S U M M A R Y
There is no evidence that aspirin improves the symptoms of vascular dementia
Low-dose aspirin can improve the prognosis of heart disease and stroke, possibly by reducing clot formation within the blood vessels
and helping to maintain or improve blood flow to the heart and brain. Many doctors assume that aspirin will also provide some benefit
for people with vascular dementia.
This systematic review shows that there is no evidence to suggest that aspirin is useful for people with vascular dementia. It is possible
that vascular dementia and stroke are caused by different pathological processes. Practitioners need to be aware of the risks of aspirin,
such as haemorrhages, which can be fatal.
B A C K G R O U N D
Description of the condition
Dementia is a syndrome consisting of a cluster of symptoms. The
core feature is cognitive impairment, whichmay include deteriora-
tion inmemory, verbal and non-verbal intellectual abilities, spatial
orientation, attention, recognition and interpretation of percep-
tions. There may also be changes in personality, motivation, and
regulation of emotions and behaviour. Each individual’s symptom
profile will depend on the areas of brain affected. The condition
progresses and occurs in clear consciousness.
Vascular dementia is a subtype of dementia and “is the result of
infarction of the brain owing to vascular disease, including hyper-
tensive cerebrovascular disease. The infarcts are usually small but
cumulative in their effect. Onset is usually in later life” (ICD 10
2010).
This term includesmulti-infarct dementia, arteriosclerotic demen-
tia, vascular dementia of acute onset, subcortical vascular demen-
tia, mixed cortical and subcortical vascular dementia, leukoariosis
and Binswanger’s disease.
Description of the intervention
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Aspirin is acetylsalicylic acid. It has analgesic, anti-pyretic, anti-
inflammatory and anti-platelet clumping properties.
In the 5th century BC Hippocrates used the bitter powder from
willow bark, which contains salicylic acid, as an anti-pyretic and
analgesic. There are worldwide historical examples of its use, for
instance by Native Americans, Middle Eastern civilisations and in
medieval England.
In 1828 the French pharmacist Leroux isolated salicylic acid, which
is also found in the wild flower, meadowsweet.
Hoffmann, working for Bayer, synthesised and sold aspirin as a
powder and in 1899 this was patented. Eleven days later Bayer also
patented the opiate heroin. In 1915 aspirin tablets were created
and in 1917 the patent expired.
Aspirin tablets are available worldwide but the dosages vary. For
instance, in the UK it is available as 75mg and 300mg tablets, and
300 mg suppositories. The standard tablet in the US is 325 mg,
the baby aspirin tablet is 81mg and in Europe aspirin is available as
100 mg tablet (cardioaspirin). The recommended analgesic dose
is 300 to 900 mg every four to six hours, while the recommended
dose for secondary prevention of thrombotic cerebrovascular and
cardiovascular disease is 75 to 300 mg daily. Low-dose aspirin is
generally defined as 75 to 300 mg/day.
How the intervention might work
Aspirin causes a non-competitive, irreversible inhibition of cyclo-
oxygenase (COX) 1, 2 and 3. Its actions vary with the dose.
At low doses (75 to 300 mg/day) it irreversibly blocks COX 1,
which is necessary for thromboxane A2 (TXA2) synthesis. Low-
ered thromboxane levels reduce platelet stickiness and reduce vaso-
constriction. Hence, at low doses (300 mg/day or less) aspirin
reduces the formation of intravascular clots and emboli and im-
proves peripheral blood flow. Low-dose aspirin has little effect on
prostaglandins.
Although aspirin is metabolised after a few hours, platelets are
unable to synthesis more COX 1 so this effect lasts several days
until more platelets are manufactured.
At high doses (1.2 to 3.6 g/day) aspirin acts predominantly
on COX 2, which converts arachidonic acid to prostaglandins
throughout the body. Thus at high doses, aspirin, like non-
steroidal anti-inflammatory drugs, reduces prostaglandin synthe-
sis and has anti-pyrexial, anti-inflammatory and analgesic proper-
ties, and can cause gastritis. The anti-inflammatory effects are me-
diated by vasoconstriction. There is little effect on platelet sticki-
ness.
Thus, aspirin affects the balance between TXA2, which promotes
aggregation of platelets and local vasoconstriction, and prostacy-
clin (PGI2), which inhibits aggregation. At low doses, aspirin de-
creases TXA2 synthesis without significantly reducing PGI2 syn-
thesis, thus reducing platelet aggregation and promoting local va-
sodilation. By this mechanism or others, low-dose aspirin can im-
prove outcomes for patients after a stroke ormyocardial infarction.
Aspirin is widely prescribed for the management of stroke and
myocardial infarction with a view to preventing further episodes.
APT 1994 found that long-term anti-platelet treatment given to
people who have suffered transient ischaemic attacks or mild is-
chaemic strokes reduced the proportional risk of non-fatal stroke
by one third and fatal stroke by one fifth. It was also suggested
that although there is some evidence that aspirin increases risk of
intracranial haemorrhage, the overall stroke rate is still reduced.
Many clinicians assume that aspirin may benefit patients with
vascular dementia by similar mechanisms and it is widely pre-
scribed for these patients (Dennis 1998). In one study of practice
by geriatricians and psychiatrists in the UK, more than 80% of
patients with cognitive impairment and vascular risk factors were
prescribed aspirin. In one survey of Canadian specialists in sub-
cortical vascular dementia (Molnar 1998), 86% of respondents
prescribed aspirin.
A retrospective case note analysis of patients with vascular demen-
tia showed a statistically insignificant trend towards both increased
life expectancy and time to institutionalisation in those regularly
taking low-dose aspirin (Devine 2003).
Aspirin has complex pharmacological actions that could affect the
progress of dementias.
If the aetiology of dementia is ischaemic, as proposed in vascular
dementia, the pharmacological effects of low-dose aspirin predict
a beneficial effect on symptoms and prognosis.
If the aetiology of any dementia is inflammatory then the mecha-
nisms of aspirin treatment suggest that high-dose aspirin may be
beneficial and improve prognosis.
However, the pharmacological effects of aspirin also predict a pos-
sible worsening of symptoms.
It is possible that aspirin causes small cerebral haemorrhages that
could stimulate the amyloid cascade, a theoretical model for
Alzheimer’s disease.
There is increasing concern that aspirin is linked to cerebral haem-
orrhages that may be primary or secondary. Again these are pre-
dicted by its known actions on platelets and small blood vessels.
It is well known that aspirin can cause gastric haemorrhages, prob-
ably via its anti-prostaglandin actions, and that these can be fatal.
As aspirin has a range of pharmacological effects it is possible that
it will be found to influence the progress of different dementias in
different ways, either beneficially or adversely.
Why it is important to do this review
It is important to do this review to determine whether aspirin im-
proves cognition or prognosis for patients with vascular dementia.
This is important because it is a widely prescribed drug and has
the potential risk of haemorrhage.
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O B J E C T I V E S
To assess the randomised trial evidence for efficacy and safety of
aspirin in the treatment of vascular dementia.
It primarily aims to assess cognitive, behavioural and global out-
comes.
The secondary objective is to assess the effect of the aspirin on
mortality, morbidity and institutionalisation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of aspirin for the treatment of vas-
cular dementia are eligible for inclusion.
Types of participants
Participants of any age with a diagnosis of vascular dementia, as
defined in the description of the condition (i.e. this term includes
multi-infarct dementia, arteriosclerotic dementia, vascular demen-
tia of acute onset, subcortical vascular dementia, mixed cortical
and subcortical vascular dementia, leukoariosis and Binswanger’s
disease).
Types of interventions
Trials assessing the effect of aspirin versus control (placebo or no
placebo), with a minimum of six months’ follow-up, were consid-
ered for inclusion, regardless of dosage.
Types of outcome measures
Primary outcomes of interest were:
• cognition, using validated scales;




• morbidity, for example, gastric and cerebral haemorrhage;
• mortality.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois - created in
part using a grant from the American Alzheimer’s Association)
- the Cochrane Dementia and Cognitive Improvement Group’s
SpecialisedRegister on 3March 2012. The search terms usedwere:
aspirin OR “acetylsalicylic acid”.
ALOIS is maintained by the Trials Search Co-ordinator of the
CochraneDementia and Cognitive ImprovementGroup and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in healthy. The studies were
identified from:
1. monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
Lilacs;
2. monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the World Health Organization
(WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the
Chinese Clinical Trials Register; the German Clinical Trials
Register; the Iranian Registry of Clinical Trials and the
Netherlands National Trials Register, plus others);
3. quarterly search of the Cochrane Central Register of
Controlled Trials (CENTRAL, The Cochrane Library);
4. six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ’methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above to cover the timeframe from the last searches performed for
ALOIS to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
The latest searches of July 2011 and March 2012, retrieved a total
of 267 and 57 results respectively. After a first-assess and a de-
duplication of these results the authors were left with 35 and 10
references from each search to assess further.
In addition, relevant websites and journals were searched for trials.
Searching other resources
Specialists in the field were approached for unpublished material
and any publications found were searched for additional refer-
ences.
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Data collection and analysis
Selection of trials
Two review authors (GR,MO) independently considered the stud-
ies identified by the search against the inclusion criteria.
Data extraction
As there were no studies suitable for inclusion in this systematic
review, data were not formally extracted.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
There were no studies eligible for the review.
Risk of bias in included studies
There were no included studies.
Effects of interventions
There were no studies eligible to be included, as updated inMarch
2012.
D I S C U S S I O N
Low-dose aspirin has been widely prescribed for patients with a
diagnosis of vascular dementia for many years. It is often assumed
that because it has confirmed benefit in stroke, it will have benefit
in vascular dementia. However, there is some evidence that the
pathogenesis of these two conditions may differ. Furthermore,
aspirin is often considered a safe treatment although evidence is
accruing that it has significant risks of haemorrhage. Therefore
both the advantages and disadvantages of prescribing low-dose
aspirin for patients with vascular dementia must be considered.
There were no eligible studies that could be included in this review.
The Meyer 1989 study was excluded on detailed inspection of its
methodology. We had wished to assess cognitive, behavioural and
global outcomes in addition to mortality, morbidity (specifically
haemorrhages) and institutionalisation data, but this was not pos-
sible.
There are difficulties in assessing the effect of aspirin in vascular
dementia. Vascular dementia is often diagnosed with reference
to a history of stroke or myocardial infarction and such patients
are likely to be taking aspirin already. This presents difficulty in
constructing a placebo-controlled trial.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review alerts the physician to the fact that despite the
widespread prescription of aspirin in patients with vascular de-
mentia, there is no empirical evidence to support this practice.
Implications for research
There is a case to be made for a multicentre randomised double-
blind placebo-controlled trial assessing the effect of aspirin on
cognition. In addition, the behavioural and global domains need
to be assessed. Mortality, morbidity and institutionalisation data
should also be measured.
However, the risk of potentially fatal haemorrhage associated with
low-dose aspirin may make such a study unethical.
It would also be useful to research the mechanism underlying the
effects of aspirin on the neurobiological bases of cognition, for
instance blood flow studies, neuroimaging and detailed neuropsy-
chological testing.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AD 2000 This was a randomised open-label trial of low-dose aspirin in 310 community-resident patients with probable
Alzheimer’s dementia and was part of a trial of donepezil. There were no significant benefits in terms of cognition
or functional abilities but the risk of haemorrhage was significantly greater in the treatment group (risk ratio 4.
4; 95% confidence interval 1.5 to 12.8; P = 0.007)
ASPREE 2008 A history of dementia was 1 of the key exclusion criteria in this protocol
Broe 2000 This was a community survey, not a treatment study
50 drugs or drug groups were categorised and their use by people with Alzheimer’s and vascular dementias analysed
Guekht 2011 3 related papers found in search; all of them had aspirin as basic treatment for patients in control and treatment
groups, with cerebrolysin as the trial drug (2008 to 2011)
Henderson 1997 This study was a community survey and was not specific for vascular dementia
Meyer 1989 The method of randomisation was alternate entry, with 4 cases who were intolerant of aspirin allocated to the
next control group slot (personal communication described in this Cochrane review 1999)
Moretti 2004 The comparison was aspirin and nimodipine versus rivastigmine
Price 2008 At entry into the study the participants did not have dementia
Richard 2010 Excluded because aspirin is only 1 element of multicomponent vascular care intervention, and the outcome is
radiological
Sturmer 1996 The study was a survey and not specific for vascular dementia
Szekely 2008 This was a large cohort study and people with vascular dementia were a very small group within it. Not a
randomised controlled trial, natural controls only
Teramoto 2010 This study evaluated the primary prevention of aspirin in older Japanese people with risk factors for cerebrovascular
and cardiovascular disease. Dementia and cognitive assessments were not included in their primary or secondary
end points. The enrolment was completed in June 2007 and follow-up was an average of 4 years so results are
imminent. Their results will be of interest in terms of risk of haemorrhages in the aspirin-treated group. So far
only rationale, design and baseline data are available
Thoonsen 2010 Poster presentation of a systematic review of the 2 papers suggesting that the pooled risk ratio of intracranial
haemorrhage in dementia patients using aspirin was 7.67 (95% confidence interval 1.73 to 34.1; P = 0.007)
Yining 2011 Excluded because aspirin was treatment as normal in both control and intervention groups
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(Continued)
Zhai 2010 Aspirin was administered to all patients in both groups
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D A T A A N D A N A L Y S E S
Comparison 1. Aspirin versus no aspirin




participants Statistical method Effect size
1 Cognition 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Behaviour 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Global 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Mortality 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.1 Aspirin related 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Other causes 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Morbidity 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 Aspirin related 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Other causes 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
A P P E N D I C E S
Appendix 1. Update search: July 2011
Source Search strategy Hits retrieved
1. ALOIS (www.medicine.ox.ac.uk/alois) Keyword search: aspirinOR“acetylsalicylic
acid”
38
2. MEDLINE In-process and other non-













12. 4 and 11
13. (2008* or 2009* or 2010* or 2011*).
ed.
14. 12 and 13
42
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(Continued)
3. EMBASE












12. 4 and 11
13. (2008* or 2009* or 2010* or 2011*).
em.







21. 14 and 20
66
4. PsycINFO










10. exp Vascular Dementia/
11. or/5-10
12. 4 and 11
13. (2008* or 2009* or 2010* or 2011*).
up.
14. 12 and 13
14
5. CINAHL (EBSCOhost) S1 (MH “Aspirin”)
S2 TX aspirin
S3 TX “acetylsalicylic acid”
S4 S1 or S2 or S3
S5 TX dementia*
S6 (MH “Dementia, Vascular”) OR (MH
“Dementia, Multi-Infarct”)
S7 TX VaD
S8 TX vascular cognitive impairment*
S9 TX VCI
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S10 S5 or S6 or S7 or S8 or S9





S16 S12 or S13 or S14 or S15
S17 S11 and S16
6. ISIWeb of Knowledge - all databases [in-
cludes: Web of Science (1945 to present);
BIOSIS Previews (1926 to present);MED-
LINE (1950 to present); Journal Citation
Reports]
Topic=(dement* OR VCI OR “vascular
congitive impairment*” OR VaD) AND
Topic=(aspirin OR “acetylsalicylic acid”)
AND Topic=(randomly OR placebo OR
groups OR trial OR RCT OR randomized
OR randomised) AND Year Published=
(2008-2011)
43
7. LILACS (BIREME) Aspirin AND dementia 6
8. CENTRAL (The Cochrane Library) (Is-
sue 4, Oct 2010)




#4 (#1 OR #2 OR #3)
#5 dementia*
#6 “vascular cognitive impairment*”
#7 VCI OR VaD
#8 (#5 OR #6 OR #7)




Interventional Studies | dementia | aspirin
OR acetylsalicylic | received from 01/01/
2008 to 07/30/2011
2
10. ICTRP Search Portal (http:/
/apps.who.int/trialsearch) [includes: Aus-
tralian New Zealand Clinical Trials Reg-
istry; ClinicalTrilas.gov; ISRCTN;Chinese
Clinical Trial Registry; Clinical Trials Reg-
istry - India; Clinical Research Informa-
tion Service - Republic of Korea; German
Clinical Trials Register; Iranian Registry
of Clinical Trials; Japan Primary Registries
Network; Pan African Clinical Trial Reg-
istry; Sri LankaClinical TrialsRegistry; The
Netherlands National Trial Register]
Interventional Studies | dementia OR VCI
OR VaD | aspirin OR acetylsalicylic | re-
ceived from 01/01/2008 to 07/30/2011
10
TOTAL before de-duplication 267
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TOTAL after de-dupe and first-assess 35
F E E D B A C K
Additional trials?
Summary
Peter Sandercock commented: “You don’t mention the results of the thrombosis prevention trial (Richards M, Meade TW, Peart S,
Brennan PJ, Mann AH (1997) Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men
at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry 62:269-72.). A further trial is planned as a
substudy to the AAA trial - contact Prof Gerry Fowkes (Gerry.Fowkes@ed.ac.uk). It may also be that theWomens health study: (Buring
J, Hennekens C, for the Womens Health Study Research Group (1992). Women’s Health Study: study design. Journal of Myocardial
Ischemia 4: 27-9) is looking prospectively at aspirin and cognitive function. There is also a small crossover study by Kellett, published
as a letter to the BMJ some years ago, but never reported in full. I think it would be worth pursuing these and mentioning them in
your next update.” (29/08/1999)
Reply
The review author replied:
“Thank you. We are aware of the studies referred to. There is increasing evidence that low dose aspirin benefits people with angina,
MIs, CVAs, and various cancers but to date there is no specific evidence that it benefits cognitive function in people with vascular
dementia”. (November 2003)
Contributors
Peter Sandercock: email: pags@skull.dcn.ed.ac.uk
Gianetta Rands: grands@doctors.org.uk
WH A T ’ S N E W
Last assessed as up-to-date: 4 March 2012.
Date Event Description
17 September 2012 New search has been performed An update search was performed for this review on 30 July 2011 and 4
March 2012. No studies were found for inclusion
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H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 2, 1999
Date Event Description
20 May 2008 New search has been performed Update search of 5 January 2008 retrieved several stud-
ies for consideration by the author. Three studies have
been added to the list of excluded studies; no studies
have been included
20 July 2005 New search has been performed July 2005: an update search was performed resulting
in two new references to one study (Moretti 2002).
There was however, no placebo group with which to
compare, so it is not known whether aspirin reduced
rate of decline over the period of the trial. Therefore
the results and conclusions of the review remain un-
changed
19 November 2003 New search has been performed November 2003: An update search was done and no
new studies were found. The reviewers dealt with
the peer reviewers’ and consumer editor’s comments.
Comments and criticisms were added
20 August 2000 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
GR: clinical and research input to reviews, drafting updates, correspondence, selection and assessment of studies, co-drafting of review,
summaries of reviewed papers.
MO: co-author and reviewer of evidence.
SW: all correspondence on original review, drafting of review, searches, selection and assessment of studies.
AS: support on previous review processes.
Contact editor: Gordon Wilcock.
Consumer editor: Owain Bennallack.
The review was peer reviewed (November 2003).
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NHS R&D, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None.
N O T E S
November 2003: an update search was done and no new studies were found. The review authors dealt with the peer reviewers’ and
consumer editor’s comments. Comments and criticisms have been added.
January 2008: updated search. No new studies to add. Excluded papers added.
March 2012: updated search. No new studies found. Excluded papers summarised and added. Increasing concerns about risks of low-
dose aspirin noted.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Inflammatory Agents, Non-Steroidal [∗therapeutic use]; Aspirin [∗therapeutic use]; Cognition Disorders [drug therapy]; Demen-
tia, Vascular [∗drug therapy; mortality]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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